Genesys Capital

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative treatments using its proprietary peptide-based technology platform, known as the Feldan Shuttle. This platform facilitates fast and safe intracellular delivery, allowing access to cellular components that are typically unreachable by conventional drugs. By leveraging the unique characteristics of the Feldan Shuttle, the company aims to create a new generation of therapeutic applications, as evidenced by its ongoing pipeline of clinical programs. Feldan Therapeutics is committed to advancing the field of intracellular therapeutics to improve patient outcomes.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

IDbyDNA, Inc. is a company specializing in metagenomics technologies aimed at identifying infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, it has developed a platform called Explify, which enables laboratories to detect and characterize pathogens using nucleic acid-based techniques. The company offers comprehensive testing services, including respiratory and research services, catering to hospitals, reference labs, clinical research institutions, and the biopharmaceutical sector. By leveraging computational biology and artificial intelligence, IDbyDNA strives to enhance diagnostic accuracy and treatment precision for infectious diseases, addressing the growing global challenge posed by these conditions.

EBT Medical, Inc. is a clinical-stage company focused on developing non-invasive neuromodulation therapies for pelvic health disorders, particularly targeting overactive bladder issues. Founded in 2014 and headquartered in Boston, Massachusetts, with an additional office in Toronto, Canada, the company emerged from scientific research conducted at the University of Toronto. EBT Medical's innovative technology aims to provide discreet treatment options that restore pelvic health function without the side effects commonly associated with traditional therapies. The company is part of a broader ecosystem designed to support patients with pelvic floor disorders.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Adapsyn Bioscience Inc. is a biotechnology company based in Hamilton, Canada, focused on the discovery and development of novel medicines derived from organic biomolecules, particularly those produced by microorganisms. Founded in 2016, the company utilizes an advanced bioinformatics platform that incorporates proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data. Its key products include various tools such as PRISM, which identifies biosynthetic gene clusters in microbial genomes; GARLIC, which defines gene clusters for natural product drug variants; the GRAPE algorithm, which reveals evolved drug fragments; and CLAMS, which matches gene clusters to compounds identified through mass spectrometry. By leveraging these innovative technologies, Adapsyn aims to uncover small molecules with unique biological activities, thereby enhancing drug discovery efforts in the biotechnology and pharmaceutical sectors.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Therapeutic Monitoring Systems Inc. is a company focused on developing and commercializing clinical decision support software designed for critical care in hospital intensive care units (ICUs) and emergency departments. Its CIMVA software platform integrates with critical care monitors to analyze patient vital signs, providing healthcare professionals with insights into patients' health statuses that are typically unavailable through standard monitoring equipment. The CIMVA Universal application further enhances this capability by allowing for the calculation and display of physiological waveform variability across multiple organ systems. Founded in 2007 and based in Ottawa, Canada, Therapeutic Monitoring Systems serves a range of customers both in the United States and internationally. The company's software aims to improve patient outcomes by leveraging big data analytics to support clinical decision-making in complex care scenarios. Currently, CIMVA is undergoing studies at various hospitals across North America to validate its effectiveness in enhancing bedside care.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.

Functional Neuromodulation is a medical technology company focused on developing neuromodulation therapies for cognitive and memory disorders, particularly Alzheimer's disease and mild cognitive impairment. Founded in 2010, the company is headquartered in Minneapolis, Minnesota, with an additional office in Toronto, Canada. It offers a deep brain stimulation (DBS) technology that involves a surgically implanted medical device designed to deliver mild electrical pulses to specific areas of the brain. This approach aims to enhance neural activity and modulate the brain's memory circuits, ultimately enabling patients with cognitive impairments to improve their quality of life.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

gIcare Pharma Inc. is a biopharmaceutical start-up established in 2011 and headquartered in Montreal, Canada. The company focuses on the development of innovative gastrointestinal drugs aimed at addressing unmet medical needs in the field of gastroenterology. gIcare Pharma is led by a skilled management team with extensive experience in this area. The company's primary objective is to create novel medications that not only benefit patients but also provide clinical advantages for healthcare providers and economic value for third-party payers. Its flagship drug candidate, GIC-1001, exemplifies this approach by offering multi-level benefits, reflecting the company's commitment to innovation in gastrointestinal treatment.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.

Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, primarily focused on the development and commercialization of implantable medical devices and skeletal tissue regeneration products for orthopedic applications in the United States and Europe. The company offers Skelite, a synthetic bone graft designed for healing and replacement, alongside products such as Primacoll and Peptos, which are aimed at stimulating bone tissue growth. Additionally, Millenium Biologix has developed ACTES, an advanced cell culture and tissue engineering system that provides automated control over biological processes involved in tissue engineering. Established in 1986, the company continues to innovate within the biomedical field.

StemPath develops therapeutic solutions for modulating body's natural regenerative capacity and endogenously replacing damaged tissues with new tissues by intervention with small molecule and biological drugs. It focuses on cardiac and skeletal muscle myopathies. The company was founded in 2002 and is based in Ottawa, Canada.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Zelos Therapeutics is a biopharmaceutical company that develops novel therapies for patients suffers from hormone-based therapeutics.